Does Anthem Cover Qsymia (Phentermine/Topiramate ER)?
The verdict
Conditional on most plans
Anthem (Elevance Health) covers Qsymia only when the employer group has elected a weight-loss or AOM benefit; carve-out plans and standard Medicare Part D exclude it entirely. Anthem's commercial and employer PPO footprint is large, so the dominant reader is a working-age patient on an employer plan: the first question is not the PA criteria but whether the employer bought AOM coverage at all. Where covered, Anthem applies BMI-based prior authorization (BMI ≥30 or ≥27 + comorbidity; behavioral program; 4-month initial; reauth on ≥3–5% weight loss). Qsymia's clinical restrictions — REMS-restricted dispensing, teratogenic topiramate requiring pregnancy monitoring, sympathomimetic CV contraindications — are mandatory clinical checks before prescribing. Anthem Medicaid is state-dependent (Elevance administers Medicaid in multiple states). The Engage cash program (~$89/month) or the 2025 generic (~$63 with coupon) is the route when excluded. Anthem commercial members may use the manufacturer savings card; Medicare and Medicaid members cannot. Anthem cells are representative composites; verify on Anthem's member drug-search.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Anthem using your member ID.
Key facts
Only 19% of firms with 200+ workers covered weight-loss drugs in their largest employer plan (2025 KFF Employer Health Benefits Survey).
KFF Employer Health Benefits Survey, Oct. 2025
Generic phentermine/topiramate ER (Teva) launched in 2025, approximately $63 with a coupon at REMS-certified pharmacies.
Drugs.com / SingleCare generic pricing, 2025
Medicare Part D has excluded weight-loss agents, including Qsymia, since 2006. The 2026 GLP-1 Bridge does not include oral AOMs.
CMS.gov / Medicare.gov GLP-1 Bridge fact sheet
Medicare vs. commercial coverage
Whether Anthem covers Qsymia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D statutorily excludes Qsymia as a weight-loss agent. This applies to all Anthem Medicare Advantage and Part D plans (marketed under various regional names including Anthem Blue Cross, Wellpoint, etc.). Qsymia is NOT in the 2026 Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), which covers only specified injectable weight-loss GLP-1s — Wegovy formulations, Foundayo, and the Zepbound KwikPen. Medicare members are ineligible for manufacturer copay cards under federal anti-kickback rules. The Engage cash program (~$89/month) or the 2025 generic (~$63 with coupon) are the routes for Anthem Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Anthem commercial and employer plans (Elevance Health's large PPO network) cover Qsymia only if the employer group has elected an AOM benefit. Per the 2025 KFF Employer Health Benefits Survey, only 19% of firms with 200+ workers covered weight-loss drugs in their largest plan. Where the AOM benefit is included, Anthem applies BMI-based prior authorization: BMI of 30 or higher, or 27 or higher with a qualifying comorbidity; concurrent behavioral modification and reduced-calorie diet program; initial 4-month approval; reauthorization requires at least 3% (FDA label) or 5% (most plans) documented weight loss. REMS dispensing restriction applies: the prescriber and dispensing pharmacy must be REMS-enrolled/certified. Topiramate teratogenicity: mandatory pregnancy testing for patients of reproductive potential before and during treatment. Sympathomimetic contraindication: phentermine is contraindicated with cardiovascular disease history. ACA marketplace plans: AOM frequently excluded. Anthem Medicaid (Elevance multi-state): AOM coverage is state-dependent; some states exclude all AOM, others cover lower-cost oral agents. Commercial members may use the Vivus manufacturer savings card (under ~$100 per fill); this card is NOT available to Medicare or Medicaid members. All cells are representative composites; verify on Anthem's member drug-search (anthem.com).
The 5 boxes you must tick to get approved
Commercial plans that will consider Qsymia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Qsymia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Qsymia brand retail: approximately $206 (Drugs.com, 3.75/23mg dose) to $283 (SingleCare) per month. Vivus Qsymia Engage home-delivery cash program: approximately $89/month (approximately $70/month on a 90-day prescription). Generic phentermine/topiramate ER (Teva, 2025): approximately $63 with a coupon at REMS-certified pharmacies.
List price with no coverage — before any manufacturer savings card.
With coverage
Where Qsymia is covered under an Anthem commercial plan with an AOM benefit, plan co-pays vary by formulary tier. Manufacturer savings card brings fills to under approximately $100 for commercially insured Anthem members. NOT available to Medicare or Medicaid members.
Typical monthly copay once prior authorization is approved.
Manufacturer savings card is available to Anthem commercial and ACA members; excluded for Medicare and Medicaid. The Engage cash program is accessible to all payers (including government-insured patients who do not bill their plan). All figures are estimates; verify with Anthem and your pharmacy.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check Anthem's member drug-search to confirm AOM benefit status
Log into anthem.com with your member ID and search for Qsymia or phentermine/topiramate ER in the drug-search or formulary tool. If no coverage appears, your plan has an AOM carve-out. Check with your HR department whether your employer plan includes the weight-loss drug benefit. Contact Anthem member services (1-800-676-2583 for commercial) if the portal is unclear.
- 2
Confirm REMS requirements and clinical screening with your prescriber
Your prescriber must be REMS-enrolled to prescribe Qsymia, and the dispensing pharmacy must be REMS-certified. Discuss topiramate's teratogenicity requirements with your prescriber — monthly pregnancy testing is mandatory for patients of reproductive potential. Also review cardiovascular history: phentermine is contraindicated with CV disease.
- 3
Use the Engage program or 2025 generic if Anthem excludes Qsymia
If your Anthem plan has an AOM carve-out, the Vivus Qsymia Engage home-delivery program (~$89/month; ~$70/month on a 90-day prescription) is the most reliable cash route and handles REMS compliance. Alternatively, the generic phentermine/topiramate ER (Teva, 2025, ~$63 with coupon) is available at REMS-certified retail pharmacies. Anthem commercial members can also use the manufacturer savings card to bring a covered fill under approximately $100.
Options if Anthem won't cover Qsymia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Qsymia Engage home-delivery cash program — ~$89/month
The primary cash route for Anthem members whose plans exclude Qsymia. Engage provides home delivery at ~$89/month (or ~$70/month on 90 days) through a REMS-compliant pharmacy. Available to all payers including government-insured patients who do not bill their plan.
Generic phentermine/topiramate ER (Teva, 2025) — ~$63 with coupon
A generic entered the market in 2025. Approximately $63 with a coupon at REMS-certified retail pharmacies — the lowest-cost Qsymia equivalent for cash-paying patients.
Contrave (naltrexone/bupropion) — Anthem covered under same AOM PA criteria
Contrave is another oral AOM covered under the same Anthem AOM PA template as Qsymia. No generic exists; the CurAccess program is ~$99/month cash. Unlike Qsymia, Contrave has no REMS or teratogenicity requirements but carries a bupropion boxed warning for suicidality.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Anthem covers Qsymia only if your employer plan includes a weight-loss or anti-obesity-medication benefit — and many employer plans do not. Medicare Part D excludes it by statute. Where covered, Anthem applies BMI-based PA (BMI ≥30 or ≥27 + comorbidity) with REMS and clinical requirements. The Engage cash program (~$89/month) or the 2025 generic (~$63) is the route when excluded. Anthem commercial members can use the Vivus savings card; Medicare and Medicaid members cannot.
No. Medicare Part D excludes Qsymia as a weight-loss agent by statute. This applies to all Anthem Medicare Advantage plans. Qsymia is not in the 2026 Medicare GLP-1 Bridge, which covers only specified injectable weight-loss GLP-1s. Anthem Medicare members seeking Qsymia pay out of pocket — Engage (~$89/month) or the 2025 generic (~$63) are the options. Manufacturer savings cards are unavailable for Medicare members under federal rules.
Yes — if you have Anthem commercial or ACA marketplace coverage and your plan includes the AOM benefit, the Vivus Qsymia manufacturer savings card can bring your fill to under approximately $100 per month. The savings card is NOT available to Anthem Medicare Advantage or Medicaid members under federal anti-kickback rules. If your Anthem plan carves out Qsymia, the Engage home-delivery cash program (~$89/month) does not require insurance coverage and is accessible regardless of plan status.
Where Anthem covers Qsymia, prior authorization requires: BMI of 30 or higher (or 27 or higher with a qualifying comorbidity such as hypertension, T2D, or sleep apnea); documented concurrent behavioral modification and dietary program; REMS-enrolled prescriber and REMS-certified pharmacy; initial 4-month approval; reauthorization on at least 3–5% documented weight loss. Topiramate teratogenicity testing and cardiovascular screening are mandatory clinical requirements regardless of PA. Cells are composites across Anthem's Elevance plans; verify on anthem.com.
All three exclude Qsymia under standard Medicare Part D. Anthem's distinguishing angle is commercial employer-carve-out variability: Anthem has a large PPO footprint, and whether Qsymia is covered depends on whether the employer elected the AOM benefit — but when covered, the Vivus savings card is usable. Humana's angle is the Medicare-first framing plus Bridge-processor irony (the Bridge doesn't cover oral AOMs). Kaiser's angle is closed-network formulary control plus Medi-Cal exclusion from 2026. For all three, Engage (~$89/month) or the 2025 generic (~$63) is the cash fallback.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Humana Cover Qsymia? 2026 | Curex
Humana Medicare Part D excludes Qsymia by law — Humana runs the GLP-1 Bridge but it does not cover oral AOMs. Engage ~$89/mo; generic from 2025.
Read moreDoes Kaiser Permanente Cover Qsymia? 2026 | Curex
Kaiser's closed HMO limits Qsymia access; Medi-Cal excluded weight-loss drugs in 2026. Engage cash program ~$89/mo; generic launched 2025.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreIf Anthem excludes Qsymia or the REMS process is a barrier, a weight-management path without insurance is available
Qsymia's REMS requirements and clinical restrictions are not a fit for everyone. Curex offers compounded semaglutide from $49/month and compounded tirzepatide from $149/month at getcurex.com/cl/glp — no insurance required, no prior authorization. Compounded semaglutide and tirzepatide are not the same medication as Qsymia. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Qsymia and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Anthem before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Qsymia and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.